Modulating immune responses to mitigate neuroinflammation, bioenergetic decrease and cognitive decline in Alzheimer’s disease
One of 545 projects Taiyo tracks in Luxembourg.
Source: EU Funding & Tenders Portal
Background and rationale: Alzheimer's disease (AD) is the main cause of dementia, with substantial socio-economic burdens. Due to the absence of a cure, understanding disease mechanisms and developing new therapies is crucial. Age-related systemic and brain inflammation contributes to cognitive decline. Inhibiting prostaglandin 2 (PGE2) - PGE2 receptor 2 (EP2) signalling has restored youthful hipp
- Status
- Under Construction
- Sector
- Government
- Location
- Luxembourg
- Updated
- 22 Jul 2026
- Source
- EU Funding & Tenders Portal
ConstructChat
Ask ConstructChat about Modulating immune responses to mitigate neuroinflammation, bioenergetic decrease and cognitive decline in Alzheimer’s disease
Pick a question to edit it, or write your own.
First answer free · no account
Project Information FAQ
Project Information
Participants
Sponsoring Agency |
Status
Original status | ongoing |
Taiyo status | Under Construction |
Taiyo last update | 2026-07-22 |
Contact
| Not available for this record. |
Description
Description | Background and rationale: Alzheimer's disease (AD) is the main cause of dementia, with substantial socio-economic burdens. Due to the absence of a cure, understanding disease mechanisms and developing new therapies is crucial. Age-related systemic and brain inflammation contributes to cognitive decline. Inhibiting prostaglandin 2 (PGE2) - PGE2 receptor 2 (EP2) signalling has restored youthful hippocampal functions in ageing mice, but its specific impact on AD-related deficits remains unclear. Aim: We seek to explore the effect of EP2 inhibition on bioenergetic and cognitive decline in an amyloid precursor protein knock-in (APP-KI) mouse model of AD, using neurobiology, immunology and data science. Objective 1: We will compare the effects of brain-penetrant and non-brain-penetrant EP2 antagonists on memory, synaptic function, glucose metabolism, systemic/brain inflammation and amyloid-beta (Aβ) pathology. Objective 2: We will study these effects in APP-KI mice injected with AD brain-derived pathological tau. We will then assess the impact of peripheral immune modulation on AD-like pathology spread. Objective 3: We will analyse the changes and interplay among synaptic dynamics, microglial activity, Aβ/tau pathology progression after EP2 inhibition via real-time imaging. Methodology: The study will involve various assessments, including behavioural tests, biochemical and immunohistochemical analyses, multianalyte assays, as well as multi-omics approaches that combine transcriptomics and metabolomics. Additionally, it will utilise two- and three-photon microscopy for live imaging. Expected results: We anticipate gaining valuable insights into a) PGE2-EP2 inhibition effects on AD-driven deficits, and b) whether peripheral immune re-programming restores brain functions beyond the blood-brain barrier. Impact: The project could yield novel mechanistic and translational outcomes, guiding non-invasive therapeutic approaches to combat AD through peripheral modulations. |
Location
Country | Luxembourg |
Source
Source | EU Funding & Tenders Portal |
URL |
More Details
Record type | Project |
Sector | Government |
Article published date | 2025-10-01 |
Research
Free account
View all details
You are reading the public part. A free account opens the rest:
- Every detail on this project
- News and media coverage
- Technical research
Free account · no card · lands you back on this project
